glp-1 drugs history The expanding landscape of medicines Researchers at UC Irvine issue

GLP-1 agonists have been shown to improve insulin secretion, decrease glucagon production, increase satiety, and help decrease food intake

doi: 10.1038/s42255-023-00966-w 62 NovikoffAMullerTD

Pharmaceutical giant Novo Nordisk recently conducted a large-scale study investigating whether weight-loss drug semaglutide could slow Alzheimers progression

(2023) Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Request that your appeal be reviewed by a board-certified endocrinologist or obesity medicine specialist

This article examines the evidence linking GLP-1 medications to muscle pain, explores potential mechanisms, and provides guidance on when to seek medical attention and how to manage symptoms effectively